RFA-OH-26-024
Continuation and Expansion of the National Mesothelioma Virtual Bank for Translational Research (U24)
Summary
National Mesothelioma Virtual Bank for Translational Research (NMVB)
The National Mesothelioma Virtual Bank for Translational Research seeks to expand a distributed biospecimen and data repository dedicated to malignant mesothelioma research. The NMVB operates as a virtual registry and tissue bank, aggregating fresh frozen tumor and control tissues, paraffin-embedded samples, blood, and DNA from mesothelioma patients across participating institutions. Beyond biospecimens, the repository curates demographic data (age, sex, race, occupational history), clinical information (stage, treatment, survival), and multi-omics datasets including genomic, transcriptomic, and proteomic data. The awardee will manage and enhance the NMVB's infrastructure, standardized data elements, and security protocols to enable discovery of early detection biomarkers, disease susceptibility markers, and prognostic indicators—ultimately supporting development of improved treatment modalities and clinical outcomes for mesothelioma patients.
- Who can apply: Institutions capable of managing a distributed biospecimen network with secure data governance and common data element standards; prior NMVB management experience likely preferred.
- Funding & project length: Not stated.
- Award mechanism: Cooperative agreement (U24).
- Key dates: Not stated.
- Best fit for: Translational oncology, occupational epidemiology, and biomarker discovery researchers seeking access to mesothelioma biospecimens, clinical metadata, and multi-omics data for early detection and prognostic studies.
Insights (6)
Biobank Management Expertise Essential for Competitive Application
This U24 cooperative agreement requires demonstrated capability in biospecimen curation, registry management, and multi-institutional data harmonization. Applicants with prior experience managing tissue banks, implementing common data elements (CDEs), and operating federated biorepository networks will be significantly more competitive than those proposing to build these systems from scratch.
Multi-Institutional Network Architecture is Core Deliverable, Not Optional
The NMVB operates as a virtual consortium where participating institutions independently manage collections but contribute to a centralized registry using standardized data elements and security protocols. Success requires the awardee to coordinate across multiple sites, negotiate data-sharing agreements, and maintain institutional buy-in—making strong existing relationships with mesothelioma research centers a substantial competitive advantage.
Omics Data Integration and Curation Differentiates Strong Applications
The opportunity explicitly emphasizes expanding genomic, transcriptomic, and proteomic data libraries alongside biospecimens. Applicants who propose concrete strategies for standardizing, curating, and making these high-dimensional datasets discoverable and interoperable will stand out; this is not a passive data repository but an active research resource requiring bioinformatics infrastructure.
Narrow Disease Focus and Established Infrastructure Limit Applicant Pool
Malignant mesothelioma is a rare disease with a small, specialized research community. The NMVB has operated since 2006, meaning the awardee must either be the incumbent or demonstrate compelling reasons to transition stewardship. This structural reality likely results in fewer competing applications but higher stakes for institutional continuity and trust.
Cooperative Agreement Mechanism Requires Substantial Ongoing NIH Engagement
U24 mechanisms involve active collaboration and oversight by the funding institute, not just grant funding. The awardee should expect regular reporting, programmatic input from NIH program staff, and alignment with broader mesothelioma research priorities. This is more demanding than an R01 or R21 and requires institutional commitment to sustained partnership.
Early Detection and Biomarker Discovery Positioning Attracts Downstream Research
The NOFO emphasizes the NMVB's role in identifying early detection markers and prognostic biomarkers. Applicants who articulate how expanded biospecimen and data access will catalyze biomarker discovery—and who can demonstrate preliminary evidence of unmet research needs—will strengthen their case for why expansion is timely and impactful.
Key Facts
Deadline
—
Posted
Thu, July 31, 2025
Award Range
$1,100,000 – $1,100,000
Expected Awards
1
Keywords
Research Areas